These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26680509)

  • 1. Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.
    Oonk S; Spitali P; Hiller M; Switzar L; Dalebout H; Calissano M; Lochmüller H; Aartsma-Rus A; 't Hoen PA; van der Burgt YE
    Proteomics Clin Appl; 2016 Mar; 10(3):290-9. PubMed ID: 26680509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibronectin is a serum biomarker for Duchenne muscular dystrophy.
    Cynthia Martin F; Hiller M; Spitali P; Oonk S; Dalebout H; Palmblad M; Chaouch A; Guglieri M; Straub V; Lochmüller H; Niks EH; Verschuuren JJ; Aartsma-Rus A; Deelder AM; van der Burgt YE; 't Hoen PA
    Proteomics Clin Appl; 2014 Apr; 8(3-4):269-78. PubMed ID: 24458521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profoundly lower muscle mass and rate of contractile protein synthesis in boys with Duchenne muscular dystrophy.
    Evans WJ; Shankaran M; Smith EC; Morris C; Nyangau E; Bizieff A; Matthews M; Mohamed H; Hellerstein M
    J Physiol; 2021 Dec; 599(23):5215-5227. PubMed ID: 34569076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
    Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
    Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
    PLoS One; 2016; 11(4):e0153461. PubMed ID: 27082433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
    Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies.
    Spitali P; Hettne K; Tsonaka R; Charrout M; van den Bergen J; Koeks Z; Kan HE; Hooijmans MT; Roos A; Straub V; Muntoni F; Al-Khalili-Szigyarto C; Koel-Simmelink MJA; Teunissen CE; Lochmüller H; Niks EH; Aartsma-Rus A
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):715-726. PubMed ID: 29682908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy.
    Strandberg K; Ayoglu B; Roos A; Reza M; Niks E; Signorelli M; Fasterius E; Pontén F; Lochmüller H; Domingos J; Ala P; Muntoni F; Aartsma-Rus A; Spitali P; Nilsson P; Szigyarto CA
    J Neuromuscul Dis; 2020; 7(3):231-246. PubMed ID: 32390640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
    Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
    Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients.
    Capitanio D; Moriggi M; Torretta E; Barbacini P; De Palma S; Viganò A; Lochmüller H; Muntoni F; Ferlini A; Mora M; Gelfi C
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):547-563. PubMed ID: 31991054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
    Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
    Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.
    Anderson J; Seol H; Gordish-Dressman H; Hathout Y; Spurney CF;
    Pediatr Cardiol; 2017 Dec; 38(8):1606-1612. PubMed ID: 28821969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.
    Murphy S; Dowling P; Zweyer M; Henry M; Meleady P; Mundegar RR; Swandulla D; Ohlendieck K
    Int J Mol Med; 2017 Jun; 39(6):1357-1370. PubMed ID: 28440464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.
    Crowe KE; Shao G; Flanigan KM; Martin PT
    J Neuromuscul Dis; 2016 May; 3(2):247-260. PubMed ID: 27854211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.
    Ayoglu B; Chaouch A; Lochmüller H; Politano L; Bertini E; Spitali P; Hiller M; Niks EH; Gualandi F; Pontén F; Bushby K; Aartsma-Rus A; Schwartz E; Le Priol Y; Straub V; Uhlén M; Cirak S; 't Hoen PA; Muntoni F; Ferlini A; Schwenk JM; Nilsson P; Al-Khalili Szigyarto C
    EMBO Mol Med; 2014 Jul; 6(7):918-36. PubMed ID: 24920607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
    Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
    J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.
    Rouillon J; Poupiot J; Zocevic A; Amor F; Léger T; Garcia C; Camadro JM; Wong B; Pinilla R; Cosette J; Coenen-Stass AM; Mcclorey G; Roberts TC; Wood MJ; Servais L; Udd B; Voit T; Richard I; Svinartchouk F
    Hum Mol Genet; 2015 Sep; 24(17):4916-32. PubMed ID: 26060189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy.
    Signorelli M; Ayoglu B; Johansson C; Lochmüller H; Straub V; Muntoni F; Niks E; Tsonaka R; Persson A; Aartsma-Rus A; Nilsson P; Al-Khalili Szigyarto C; Spitali P
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):505-517. PubMed ID: 31881125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients.
    Awano H; Matsumoto M; Nagai M; Shirakawa T; Maruyama N; Iijima K; Nabeshima YI; Matsuo M
    Clin Chim Acta; 2018 Jan; 476():111-116. PubMed ID: 29175173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of serum protein biomarkers for utrophin based DMD therapy.
    Guiraud S; Edwards B; Squire SE; Babbs A; Shah N; Berg A; Chen H; Davies KE
    Sci Rep; 2017 Mar; 7():43697. PubMed ID: 28252048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.